LOGILIA (ulipristal acetate) by Teva is occur, ella postpones follicular rupture. Approved for pregnancy following unprotected intercourse, a known, suspected contraceptive failure. First approved in 2017.
Drug data last refreshed 18h ago
occur, ella postpones follicular rupture. The likely primary mechanism of action of ulipristal acetate for emergency contraception is therefore inhibition or delay of ovulation; however, alterations to the endometrium that may affect implantation may also contribute to efficacy.
Worked on LOGILIA at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Mammogram Pretreatment With Ulipristal Acetate
Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive
Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned
Study of Ulipristal Acetate in Female Patients With Moderately or Severely Impaired Renal Function, Compared With Matched Healthy Female Subjects
Adenomyosis and Ulipristal Acetate